Otolaryngology Doctors in Huntersville, NC Accepting Medicare

3 Otolaryngology doctors found. Showing 1 - 3

Stan D. Phillips, M.D Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 9710 Sam Furr Rd, Unit D, Huntersville, NC 28078 Phone: 704-896-1909

Dr. Todd R Reulbach, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 10305 Hamptons Park Drive, Suite 201, Huntersville, NC 28078 Phone: 704-295-3600    Fax: 704-892-3181

Dr. Mark Turner Weigel, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 10305 Hamptons Park Drive, Suite 201, Huntersville, NC 28078 Phone: 704-295-3600    Fax: 704-892-3181

News Archive

Psoriasis drug also effective at reducing aortic inflammation

Ustekinumab, sold under the name Stelara, is approved by the U.S. Food and Drug Administration to treat psoriasis, psoriatic arthritis, and Crohn's Disease. Researchers wanted to know if the benefits of the drug go beyond clearing the skin.

Preparing for better management of Tamiflu-resistant influenza viruses

Researchers in Umeå and Uppsala have found that residues of the influenza drug Tamiflu in our environment can make the influenza virus in birds resistant. This can have serious consequences in the event of an influenza pandemic. With more than 14 million SEK from the Swedish Research Councils Formas and VR, the research team will now continue their studies with a focus on alternative antiviral drugs.

Companies with culture of health may yield greater value for their investors

Companies that build a culture of health by focusing on the well-being and safety of their workforce may yield greater value for their investors, according to a study published in the September issue of the Journal of Occupational and Environmental Medicine (JOEM), official publication of the American College of Occupational and Environmental Medicine (ACOEM).

XOMA sells royalty interest in CIMZIA

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced today that it has sold its royalty interest in CIMZIA® (certolizumab pegol) marketed by UCB S.A. for $4 million to an undisclosed buyer. The manufacture of CIMZIA is covered by a license to XOMA's Bacterial Cell Expression technology.

Read more Medical News

› Verified 8 days ago